Kurt de Vlam

8.9k total citations · 2 hit papers
172 papers, 3.8k citations indexed

About

Kurt de Vlam is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Kurt de Vlam has authored 172 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Rheumatology, 86 papers in Immunology and 58 papers in Hematology. Recurrent topics in Kurt de Vlam's work include Spondyloarthritis Studies and Treatments (123 papers), Psoriasis: Treatment and Pathogenesis (83 papers) and Rheumatoid Arthritis Research and Therapies (82 papers). Kurt de Vlam is often cited by papers focused on Spondyloarthritis Studies and Treatments (123 papers), Psoriasis: Treatment and Pathogenesis (83 papers) and Rheumatoid Arthritis Research and Therapies (82 papers). Kurt de Vlam collaborates with scholars based in Belgium, United States and United Kingdom. Kurt de Vlam's co-authors include Rik Lories, Frank P. Luyten, Anna Beutler, Cynthia Guzzo, Christian Antoni, Gerald G. Krueger, C. Birbara, Philip J. Mease, L T Dooley and Bin Zhou and has published in prestigious journals such as JAMA, The Journal of Immunology and Gastroenterology.

In The Last Decade

Kurt de Vlam

157 papers receiving 3.7k citations

Hit Papers

Infliximab improves signs and symptoms of psoriatic arthr... 2005 2026 2012 2019 2005 2019 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
    2005 553 citations Kurt de Vlam, Anna Beutler et al. Annals of the Rheumatic Diseases profile →
  2. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy
    2019 224 citations Kurt de Vlam et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kurt de Vlam Belgium 28 3.2k 2.0k 1.4k 286 211 172 3.8k
Atul Deodhar United States 27 2.5k 0.8× 1.7k 0.9× 1.0k 0.7× 180 0.6× 123 0.6× 125 3.0k
Jieruo Gu China 28 2.8k 0.9× 1.4k 0.7× 973 0.7× 636 2.2× 128 0.6× 166 3.9k
Feng Huang China 26 2.1k 0.7× 1.2k 0.6× 827 0.6× 366 1.3× 91 0.4× 102 3.0k
C. Birbara United States 23 3.8k 1.2× 1.9k 1.0× 1.8k 1.2× 354 1.2× 186 0.9× 43 5.5k
Rubén Queiró Spain 30 1.9k 0.6× 1.9k 1.0× 877 0.6× 243 0.8× 425 2.0× 192 2.9k
Nigil Haroon Canada 28 2.4k 0.8× 1.4k 0.7× 890 0.6× 467 1.6× 71 0.3× 123 2.9k
Antonio Marchesoni Italy 37 5.2k 1.6× 3.6k 1.9× 2.3k 1.6× 367 1.3× 409 1.9× 144 6.4k
Ennio Lubrano Italy 32 2.5k 0.8× 1.9k 1.0× 1.1k 0.8× 139 0.5× 148 0.7× 196 3.2k
R. B. M. Landewé Netherlands 22 5.0k 1.6× 2.1k 1.1× 1.8k 1.2× 350 1.2× 111 0.5× 65 5.7k
Cédric Lukas France 27 2.7k 0.9× 929 0.5× 877 0.6× 206 0.7× 51 0.2× 112 3.3k

Countries citing papers authored by Kurt de Vlam

Since Specialization
Citations

This map shows the geographic impact of Kurt de Vlam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kurt de Vlam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kurt de Vlam more than expected).

Fields of papers citing papers by Kurt de Vlam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kurt de Vlam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kurt de Vlam. The network helps show where Kurt de Vlam may publish in the future.

Co-authorship network of co-authors of Kurt de Vlam

This figure shows the co-authorship network connecting the top 25 collaborators of Kurt de Vlam. A scholar is included among the top collaborators of Kurt de Vlam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kurt de Vlam. Kurt de Vlam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Taylor, Peter C., Philip J. Mease, Kurt de Vlam, et al.. (2025). Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Annals of the Rheumatic Diseases. 84(6). 979–991. 2 indexed citations
3.
Proft, Fabian, Vinod Chandran, Wilson Liao, et al.. (2025). Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative. Nature Reviews Rheumatology. 22(2). 132–144.
4.
Mechelen, Margot Van, Sofia Pazmiño, Barbara Neerinckx, et al.. (2025). Low apolipoprotein A1 and high apolipoprotein B levels indicate specific lipid changes in treatment naïve early psoriatic arthritis. RMD Open. 11(1). e005174–e005174.
5.
Chandran, Vinod, Wilson Liao, & Kurt de Vlam. (2024). Biomarkers in Psoriasis and Psoriatic Arthritis: Where Are We Now?. The Journal of Rheumatology. 51(Suppl 2). 74–76. 1 indexed citations
6.
Swinnen, Thijs Willem, et al.. (2024). High-quality research on physical therapy in psoriatic arthritis is needed: a systematic review. Rheumatology Advances in Practice. 8(3). rkae107–rkae107. 1 indexed citations
7.
Armstrong, April W., Tarannum Jaleel, Joseph F. Merola, et al.. (2024). Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity. Dermatology and Therapy. 14(6). 1615–1631. 1 indexed citations
8.
Lubrano, Ennio, Silvia Scriffignano, Kurt de Vlam, et al.. (2023). Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise – a review. RMD Open. 9(3). e003339–e003339. 12 indexed citations
9.
Ng, Beverly, Deepak R. Jadon, Frank Behrens, et al.. (2023). Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting. The Journal of Rheumatology. 50(Suppl 2). 61–65. 1 indexed citations
10.
Pazmiño, Sofia, et al.. (2023). Comorbidities in Early Psoriatic Arthritis: Data From the Metabolic Disturbances in Psoriatic Arthritis Cohort Study. Arthritis Care & Research. 76(2). 231–240. 13 indexed citations
11.
Kuijk, Arno W. R. van, Michael T. Nurmohamed, Stefan Siebert, et al.. (2023). Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data. Lara D. Veeken. 62(10). 3382–3390. 14 indexed citations
12.
13.
Hooge, Manouk de, Ann‐Sophie De Craemer, Serge Steinfeld, et al.. (2023). Extent of axial damage in psoriatic arthritis and spondyloarthritis: comparative data from the BEPAS and (Be-)GIANT multicentre cohorts. RMD Open. 9(2). e002994–e002994. 3 indexed citations
14.
Campanholo, Cristiano, Ajesh B. Maharaj, Luisa Costa, et al.. (2022). Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. The Journal of Rheumatology. 50(3). jrheum.220310–jrheum.220310. 20 indexed citations
15.
16.
Gossec, Laure, Stefan Siebert, Paul Bergmans, et al.. (2022). Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Annals of the Rheumatic Diseases. 82(4). 496–506. 16 indexed citations
17.
Deodhar, Atul, Philip J. Mease, Proton Rahman, et al.. (2020). Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial. Rheumatology and Therapy. 8(1). 135–150. 11 indexed citations
18.
Vlam, Kurt de, et al.. (2018). Spondyloarthritis in the Democratic Republic of the Congo: a prospective hospital-based study. BMJ Open. 8(5). e020329–e020329. 8 indexed citations
19.
Wittoek, Ruth, et al.. (2008). Agreement between evidence and Belgian rheumatologists' experience on the use of DMARDs for arthritis and/or enthesitis in ankylosing spondylitis. Clinical and Experimental Rheumatology. 26(4). 742–742. 2 indexed citations
20.
Gómez‐Reino, Juan J., D Halter, Kurt de Vlam, et al.. (2007). Treatment with infliximab is associated with "Major clinical response" in psoriatic arthritis patients treated with infliximab: Analysis of two double-blind placebo controlled trials.. Document Server@UHasselt (UHasselt). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Atul Deodhar Breakdown of academic impact, for papers by Jieruo Gu Breakdown of academic impact, for papers by Feng Huang Breakdown of academic impact, for papers by C. Birbara Breakdown of academic impact, for papers by Rubén Queiró Breakdown of academic impact, for papers by Nigil Haroon Breakdown of academic impact, for papers by Antonio Marchesoni Breakdown of academic impact, for papers by Ennio Lubrano Breakdown of academic impact, for papers by R. B. M. Landewé Breakdown of academic impact, for papers by Cédric Lukas
Rankless by CCL
2026